Abstract

Antibody Based Cancer Immunotherapy

Christian Klein, Expert Scientist/Head, Roche Pharmaceutical Research & Early Development/Roche Innovation Center Zurich

Cancer immunotherapy has emerged as key modality to achieve long term response in cancer therapy. A number of antibody-based cancer immunotherapies has been approved recently and/or is currently being investigated in clinical trials e.g. ADCC enhanced antibodies, T cell bispecific antibodies, checkpoint inhibitory antibodies, T cell agonistic antibodies, and adoptive T cell therapy. In this keynote lecture on overview about novel approaches to antibody based cancer immunotherapy currently in clinical development by Roche Pharmaceutical Research and Early Development will be given.  The lecture will cover the development of obinutuzumab, a novel glycoengineered Type II CD20 antibody, and how to improve the immune effector function of antibodies, CEA-IL2v and FAP-IL2v, representing a novel class of IL2v based immunocytokines and an overview about a novel T cell bispecific antibody platform.